Aprea discloses second clinical hold in a week, this time for lymphoma study
Barely a week after Aprea got hit with a clinical hold on a slate of myeloid malignancy trials, the biotech revealed its lymphoid malignancy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
